230 related articles for article (PubMed ID: 27197726)
21. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
22. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
23. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
[TBL] [Abstract][Full Text] [Related]
24. Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?
Elshafei A; Moussa AS; Hatem A; Ethan V; Panumatrassamee K; Hernandez AV; Jones JS
Urology; 2013 Apr; 81(4):826-30. PubMed ID: 23434102
[TBL] [Abstract][Full Text] [Related]
25. Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O; Badilla S
Urol Oncol; 2015 May; 33(5):203.e19-25. PubMed ID: 25746939
[TBL] [Abstract][Full Text] [Related]
26. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
Murray NP; Fuentealba C; Reyes E; Jacob O
Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
[TBL] [Abstract][Full Text] [Related]
28. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
Remzi M; Fong YK; Dobrovits M; Anagnostou T; Seitz C; Waldert M; Harik M; Marihart S; Marberger M; Djavan B
J Urol; 2005 Oct; 174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261. PubMed ID: 16145388
[TBL] [Abstract][Full Text] [Related]
29. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy.
Ruffion A; Devonec M; Champetier D; Decaussin-Petrucci M; Rodriguez-Lafrasse C; Paparel P; Perrin P; Vlaeminck-Guillem V
Int J Mol Sci; 2013 Aug; 14(9):17767-80. PubMed ID: 23994838
[TBL] [Abstract][Full Text] [Related]
30. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.
Moussa AS; Kattan MW; Berglund R; Yu C; Fareed K; Jones JS
BJU Int; 2010 Feb; 105(3):352-8. PubMed ID: 19681898
[TBL] [Abstract][Full Text] [Related]
31. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
32. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
[TBL] [Abstract][Full Text] [Related]
33. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.
Zhou ZH; Liu F; Wang WJ; Liu X; Sun LJ; Zhu Y; Ye DW; Zhang GM
Asian J Androl; 2021; 23(1):41-46. PubMed ID: 32503957
[TBL] [Abstract][Full Text] [Related]
35. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
36. A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.
Ouzaid I; Yates DR; Hupertan V; Mozer P; Chartier-Kastler E; Haertig A; Bitker MO; Rouprêt M
Prostate; 2012 Aug; 72(11):1200-6. PubMed ID: 22213470
[TBL] [Abstract][Full Text] [Related]
37. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
[TBL] [Abstract][Full Text] [Related]
38. Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.
Nowroozi MR; Amini S; Kasaeian A; Zavarehei MJ; Eshraghian MR; Ayati M
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e289-97. PubMed ID: 24684767
[TBL] [Abstract][Full Text] [Related]
39. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G
Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
